Published in Blood Weekly, November 25th, 2004
"It's gratifying that our strategy to monetize FOSRENOL, that culminated earlier this year in our agreement with Shire, will strengthen our cash position as we head towards pivotal trials for AMD3100 in stem-cell transplant for cancer patients," said Dr. Michael Abrams, AnorMED's president and CEO.
In March 2004, AnorMED sold the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.